Description
Market Report Coverage – SERD Therapeutics
Market Segmentation
• By Product – Faslodex, RAD1901, GDC-9545, AZD9833, SAR439859, Other Generics
• By Application – First-line treatment and second-line treatment
Regional Segmentation
• North America – U.S., Canada
• Europe – Germany, France, U.K., Italy, Spain, and Rest-of-Europe
• Asia-Pacific – China, Japan, and Rest-of-Asia-Pacific (RoAPAC)
• Rest-of-the-World
Growth Drivers
• Rising incidence of breast cancer
• Advanced route of administration: oral drug delivery
Market Challenges
• Resistance to endocrine therapy
Market Opportunities
• SERDs as combination therapy
• Therapeutic potential in different types of cancer
Key Companies Profiled
AstraZeneca, Plc, Novartis AG, Sanofi S.A, Hofmann-la Roche AG, G1 Therapeutics, Zentalis Pharmaceuticals, Zenopharm LLC, Radius Health, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd, InventisBio, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, HBT Labs, and Amneal pharmaceuticals, Inc.
Key Questions Answered in this Report:
• What is SERD therapy?
• How did the SERD therapy market evolve, and what is its scope in the future?
• What are the major market drivers, restraints, and opportunities in the global SERD therapeutics market?
• What are the key developmental strategies that are being implemented by the key players to sustain this market?
• What is the impact of generics on branded therapy?
• What is the impact of COVID-19 on this market?
• What are the guidelines implemented by different government bodies to regulate the approval of products to be used in breast cancer treatment?
• How is SERD therapy being utilized for the treatment of postmenopausal women with breast cancer?
• What was the market size of the leading segments and sub-segments of the global SERD therapeutics market in 2019?
• How will the industry evolve during the forecast period 2020-2030?
• What will be the growth rate of the SERD therapeutics market during the forecast period?
• How will each segment of the global SERD therapeutics market grow during the forecast period, and what will be the revenue generated by each segment by the end of 2030?
• Which product segment and application segment are expected to register the highest CAGR for the global SERD therapeutics market?
• What is the market size of the SERD therapeutics market in different countries of the world?
• Which geographical region is expected to contribute to the highest sales in the global SERD therapeutics market?
• What is the regulatory framework for the SERD therapeutics market in different regions?
• What are the key strategies incorporated by the players of the global SERD therapeutics market to sustain the competition and retain their supremacy?
Market Overview
The unmet clinical benefits and quest for novel therapies with better efficacy and safety to improve the quality of life in patients living with breast cancer treatment, complete estrogen receptor inhibition, and resistance to multiple endocrine therapies led to the discovery of SERD therapies. SERD therapy has been extensively accepted and used as both monotherapy and in combination with other therapeutic agents. The potential of SERD therapy in breast cancer treatment is yet to be fully discovered, thus leaving a substantial scope of innovation and research in the field.
The global SERD therapeutics market was valued at $1000.2 million in 2019 and is expected to reach $4085.0 million by 2030, witnessing a CAGR of 16.66% during the forecast period 2020-2030. The market growth can mainly be attributed to the increasing breast cancer incidence and mortality worldwide, increasing number of relapsed or refractory cases in breast cancer, unmet clinical benefits with existing breast cancer treatments targeting hormone receptor-positive metastatic breast cancer, eased route of administration and dosage exposure, rising focus of the key players on research and development (R&D) activity for new product launch, and increased government and private funding for improved safety and outcomes provided by SERD therapy.
The global SERD therapeutics market is expected to witness high growth in the future. The increasing global breast cancer incidence and mortality and increased demand for endocrine therapies that cure chronic conditions completely and improve the quality of life of patients are the major factors anticipated to contribute to the growth of the global SERD therapeutics market.
Furthermore, the increasing number of relapsed or refractory cases in breast cancer, unmet clinical benefits with existing breast cancer treatments targeting hormone receptor-positive metastatic breast cancer, painful route of administration and limited dosage exposure will augment the SERD therapeutics market. Also, the increased use of SERDs as combination therapy with other endocrine agents and rising focus of the key players on research and development (R&D) activity for new product launch is expected to drive the market. Rise in government and private funding for improved safety and outcomes provided by SERD therapy are additional factors propelling the growth.
Within the research report, the market is segmented based on therapy type, product, region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The global SERD therapeutics market is currently dominated by Sandoz, Mylan N.V., Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories, Accord Healthcare, and Teva Pharmaceuticals Industries Ltd. The market dominance of these companies can be attributed to cost-effective generic fulvestrant availability in the market. As of 2018, AstraZeneca Plc was the only company to offer SERD therapy in the global SERD therapeutics market. The company has now witnessed a sharp decline after generic launch in several regions. With the pipeline of SERD therapeutics, the market is expected to augment tremendously. Some of the major companies with strong and early pipeline include Sanofi S.A., Hoffmann-La Roche AG, Radius Health, and AstraZeneca Plc.
Based on region, North America is the leading contributor to the SERD therapeutics market in terms of revenue. The growing breast cancer incidence, relapse from existing endocrine therapies, and the substantial research and development made in the field are consequentially promoting the growth of the North America SERD therapeutics market. Also, the Asia-Pacific and Europe regions are expected to register the high CAGR during the forecast period of 2020-2030.
Table of Contents
Executive Summary
1 Definition
1.1 Inclusion and Exclusion Criteria
2 Research Scope
2.1 Target Audience
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 SERD Therapeutics: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 Market Overview
4.1 Definition
4.2 Progression in SERD Therapeutics
4.3 SERD Therapeutics: Mechanism of Action
4.4 SERD Therapeutics: Forms of Administration
4.5 SERD Therapeutics Market and Growth Potential, 2019-2030
4.6 Impact of Novel Drugs on Available Therapies
5 Epidemiology of Breast Cancer
5.1 Overview
5.2 Breast Cancer Classification
5.2.1 Types of Breast Cancer
5.2.2 Molecular Subtypes of Breast Cancer
5.2.3 Stages of Breast Cancer
5.2.4 Population (Premenopausal and Postmenopausal)
5.2.5 Breast Cancer Incidence and Mortality (by Region), 2020
5.2.6 Role of Molecular Biomarkers in Breast Cancer Treatment
5.3 SERDs in Breast Cancer Treatment
5.4 Breast Cancer in Male
6 SERD Therapeutics Clinical Trials Landscape
6.1 Overview
6.2 SERD Therapeutics Clinical Trials Current Scenario
7 Impact of COVID-19 on SERD Therapeutics
7.1.1 Impact of COVID-19 on Breast Cancer Treatment
7.1.2 Impact of COVID-19 on Global SERD Therapeutics Market Growth Rate
7.1.3 Clinical Trial Disruptions and Resumptions
8 Global SERD Commercialized and Pipeline Therapeutics
8.1 Commercialized Therapeutics
8.2 Faslodex Overview
8.3 Faslodex Pricing and Reimbursement Scenario
8.3.1 Faslodex Sales Analysis
8.3.2 Generic Fulvestrant Overview
8.3.2.1 Impact of Generic Fulvestrant on Faslodex Global Revenue
8.4 Pipeline Therapeutics
9 Industry Insights
9.1 Overview
9.2 Regulatory Scenario of Endocrine Therapy
9.3 Legal Requirements and Frameworks in the U.S.
9.3.1 Clinical Trial Authorization
9.3.2 Marketing Authorization
9.3.3 USFDA Guidelines for NDA Submission
9.3.4 Post-Authorization Regulations
9.4 Legal Requirements and Frameworks in Europe
9.4.1 Centralized Procedure
9.4.2 Decentralized Procedure
9.4.3 Mutual-Recognition Procedure
9.4.4 National Procedure
9.5 Legal Requirements and Frameworks in Asia-Pacific
9.5.1 Legal Requirements and Frameworks in China
9.5.2 Legal Requirements and Frameworks in Japan
9.6 Expedited Regulatory Designations Around the World
10 Market Dynamics
10.1 Impact Analysis
10.2 Market Drivers
10.2.1 Rising Incidence of Breast Cancer
10.2.2 Advanced Route of Administration: Oral Drug Delivery
10.3 Market Restraints
10.3.1 Resistance to Endocrine Therapy
10.4 Market Opportunities
10.4.1 SERDs as Combination Therapy
10.4.2 Therapeutic Potential in Different Types of Cancers
11 Global SERD Therapeutics Market (by Therapy)
11.1 Overview
11.2 First-Line Treatment
11.3 Second-Line Treatment
12 Global SERD Therapeutics Market (by Product)
12.1 Overview
12.2 Faslodex
12.3 RAD1901
12.4 GDC-9545
12.5 AZD9833
12.6 SAR439859
12.7 Other Generics
13 Global SERD Therapeutics Market (by Region)
13.1 North America
13.1.1 U.S.
13.1.2 Canada
13.2 Europe
13.2.1 U.K.
13.2.2 Germany
13.2.3 France
13.2.4 Italy
13.2.5 Spain
13.2.6 Rest-of-Europe
13.3 Asia-Pacific
13.3.1 China
13.3.2 Japan
13.3.3 Rest-of-APAC
13.4 Rest-of-the-World
14 Competitive Landscape
14.1 Key Developments and Strategies
14.1.1 Regulatory and Legal Developments
14.1.1.1 Synergistic Activities
14.1.1.2 Mergers and Acquisitions (M&A) Activities
14.1.1.3 Funding and Business Strategy Activities
14.2 Market Share Analysis
15 Company Profiles
15.1 Overview
15.2 Amneal Pharmaceuticals Inc
15.2.1 Company Overview
15.2.2 Role of Amneal Pharmaceuticals Inc in the Global SERD Therapeutics Market
15.2.3 Financials
15.2.4 R&D Expenditure, 2017-2019
15.2.5 SWOT Analysis
15.3 AstraZeneca, Plc.
15.3.1 Company Overview
15.3.2 Role of AstraZeneca, Plc. in the Global SERD Therapeutics Market
15.3.3 Financials
15.3.4 R&D Expenditure, 2017-2019
15.3.5 SWOT Analysis
15.4 Dr. Reddy’s Laboratories
15.4.1 Company Overview
15.4.2 Role of Dr. Reddy’s Laboratories in the Global SERD Therapeutics Market
15.4.3 Financials
15.4.4 R&D Expenditure, 2017-2019
15.4.5 SWOT Analysis
15.5 Eli Lilly and Company
15.5.1 Company Overview
15.5.2 Role of Eli Lilly and Company in the Global SERD Therapeutics Market
15.5.3 Financials
15.5.4 R&D Expenditure, 2017-2019
15.5.5 SWOT Analysis
15.6 G1 Therapeutics, Inc.
15.6.1 Company Overview
15.6.2 Role of G1 Therapeutics, Inc. in the Global SERD Therapeutics Market
15.6.3 Financials
15.6.4 R&D Expenditure, 2017-2019
15.6.5 SWOT Analysis
15.7 Glenmark Pharmaceuticals
15.7.1 Company Overview
15.7.2 Role of Glenmark Pharmaceuticals in the Global SERD Therapeutics Market
15.7.3 Financials
15.7.4 R&D Expenditure, 2017-2019
15.7.5 SWOT Analysis
15.8 HBT Labs, Inc
15.8.1 Company Overview
15.8.2 Role of HBT Labs, Inc in the Global SERD Therapeutics Market
15.8.3 SWOT Analysis
15.9 Hoffmann-La Roche AG
15.9.1 Company Overview
15.9.2 Role of Hoffmann-La Roche AG in the Global SERD Therapeutics Market
15.9.3 Financials
15.9.4 R&D Expenditure, 2017-2019
15.9.5 SWOT Analysis
15.10 InventisBio
15.10.1 Company Overview
15.10.2 Role of InventisBio in the Global SERD Therapeutics Market
15.10.3 SWOT Analysis
15.11 Novartis AG
15.11.1 Company Overview
15.11.2 Role of Novartis AG in the Global SERD Therapeutics Market
15.11.3 Financials
15.11.4 R&D Expenditure, 2017-2019
15.11.5 SWOT Analysis
15.12 Radius Health
15.12.1 Company Overview
15.12.2 Financials
15.12.3 R&D Expenditure, 2017-2019
15.12.4 SWOT Analysis
15.13 Sanofi S.A.
15.13.1 Company Overview
15.13.2 Financials
15.13.3 R&D Expenditure, 2017-2019
15.13.4 SWOT Analysis
15.14 Teva Pharmaceutical Industries Ltd.
15.14.1 Company Overview
15.14.2 Role of Teva Pharmaceutical Industries Ltd. in the SERD Therapeutics Market
15.14.3 Financials
15.14.4 R&D Expenditure, 2017-2019
15.14.5 SWOT Analysis
15.15 Zenopharm LLC.
15.15.1 Company Overview
15.15.2 Role of Zenopharm LLC in the Global SERD Therapeutics Market
15.15.3 SWOT Analysis
15.16 Zentalis Pharmaceuticals
15.16.1 Company Overview
15.16.2 Role of Zentalis Pharmaceuticals in the Global SERD Therapeutics Market
15.16.3 Financials
15.16.4 R&D Expenditure, 2017-2019
15.16.5 SWOT Analysis
List of Tables
Table 1: Leading Players in Global SERD Therapeutics Market
Table 4.1: Available Novel Therapies in Breast Cancer
Table 6.1: SERDs Undergoing Clinical Development and Trial Design
Table 7.1: Impact of COVID-19 on SERDs Clinical Trials
Table 8.1: Generic Fulvestrant Approvals by USFDA, 2019-2020
Table 9.2: Expedited Regulatory Designations Around the World
Table 15.1: AstraZeneca Plc: Pipeline Product Portfolio
Table 15.2: Eli Lilly and Company: Pipeline Product Portfolio
Table 15.3: G1 Therapeutics, Inc.: Pipeline Product Portfolio
Table 15.4: Hoffmann-La Roche AG: Pipeline Product Portfolio
Table 15.5: InventisBio: Pipeline Product Portfolio
Table 15.6: Novartis AG: Pipeline Product Portfolio
Table 15.7: Radius Health: Pipeline Product Portfolio
Table 15.8: Sanofi S.A.: Pipeline Product Portfolio
Table 15.9: Zenopharm LLC: Pipeline Product Portfolio
Table 15.10: Zentalis Pharmaceutical.: Pipeline Product Portfolio
List of Figures
Figure 1: Top Five Cancers with the Highest Incidence, 2020
Figure 2: Leading Mortality Cancers, 2020
Figure 3: Global SERD Therapeutics Clinical Trials (by Phase)
Figure 4: Global SERD Therapeutics Market, $Million, 2019-2030
Figure 5: Global SERD Therapeutics: Impact Analysis
Figure 6: Share of Key Developments and Strategies, January 2017-December 2020
Figure 7: Global SERD Therapeutics Market (by Therapy), 2019 and 2030
Figure 8: Global SERD Therapeutics Market (by Product)
Figure 9: Global SERD Therapeutics Market (by Region), 2019 and 2030
Figure 2.1: Global SERD Therapeutics Market Segmentation
Figure 3.1: Global SERD Therapeutics Market Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Chemical Classes of SERDs
Figure 4.2: SERD Therapeutics Development
Figure 4.3: SERDs Mechanism of Action
Figure 4.4: SERDs Route of Administration
Figure 4.5: SERD Therapeutics Market Growth Revenue, 2019-2030
Figure 5.1: Breast Cancer Types and Subtypes
Figure 5.2: Most Common Types of Breast Cancer
Figure 5.3: Female Breast Cancer Cases (by Subtype), U.S., 2013-2017
Figure 5.4: Breast Cancer Classification (by Stage)
Figure 5.5: Global Premenopausal and Postmenopausal Breast Cancer ASIR, 2018
Figure 5.6: Female Breast Cancer New Cases (by Age Group), U.S., 2012-2016
Figure 5.7: Geographies with the Highest ASIR for Female Breast Cancer, 2020
Figure 5.8: Geographies with the Highest Age-Standardized Mortality Rate for Female Breast Cancer, 2020
Figure 5.9: Few Categories of Molecular Biomarkers in Breast Cancer
Figure 5.10: Male Breast Cancer Risk Factors
Figure 6.1: SERD Therapeutics Global Clinical Trials (by Phase), 2020
Figure 7.1: Estimated Overall Excess Deaths from Breast Cancers in the U.S. Due to COVID-19, 2020-2030
Figure 7.2: COVID-19 Impact on SERD Therapeutics Market
Figure 7.3: Impact of COVID-19 on Clinical Trials
Figure 8.1: Faslodex FDA Approval Timeline in the U.S.
Figure 8.2: Faslodex Treatment Dosing Regimen
Figure 8.3: Faslodex Global Revenue, 2015-2018
Figure 8.4: Geography-Specific Faslodex Revenue, 2015-2018
Figure 8.5: Impact of Generic Fulvestrant on Global Sales of Faslodex, 2018-2020
Figure 8.6: Dose Regimen of Some Oral SERDs in Pipeline
Figure 9.1: Clinical Trial Authorization for Endocrine Therapy in the U.S.
Figure 9.2: Steps for Obtaining Marketing Authorization
Figure 9.3: USFDA Review Timeline
Figure 9.4: EMA Drug License Application Process and Review Timeline
Figure 10.1: Global SERD Therapeutics Market: Impact Analysis
Figure 10.2: Estimated Incidence of Breast Cancer Worldwide, 2020-2040
Figure 10.3: Risk Factors Related to Breast Cancer
Figure 10.4: Potential Resistance Mechanisms to Endocrine Therapy
Figure 10.5: SERDs in Combination with Other Therapeutic Agents
Figure 10.6: SERDs Potential in Different Types of Cancers
Figure 11.1: Revenue Contribution of Global SERD Therapeutics Market (by Therapy), $Million, 2019 and 2030
Figure 11.2: Global SERD Therapeutics Market (First-Line Treatment), $Million, 2019-2030
Figure 11.3: Global SERD Therapeutics Market (Second-Line Treatment), $Million, 2019-2030
Figure 12.1: Global SERD Therapeutics Market (by Product), $Million, 2019 and 2030
Figure 12.2: Global SERD Therapeutics Market (Faslodex), $Million, 2019-2030
Figure 12.3: Global SERD Therapeutics Market (RAD1901), $Million, 2019-2030
Figure 12.4: Global SERD Therapeutics Market (GDC-9545), $Million, 2019-2030
Figure 12.5: Global SERD Therapeutics Market (AZD9833), $Million, 2019-2030
Figure 12.6: Global SERD Therapeutics Market (SAR439859), $Million, 2019-2030
Figure 12.7: Global SERD Therapeutics Market (Other Generics), $Million, 2019-2030
Figure 13.1: Global SERD Therapeutics Market (by Region)
Figure 13.2: Global SERD Therapeutics Market (by Region), 2019 and 2030
Figure 13.3: North America SERD Therapeutics Market, $Million, 2019-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: Revenue Contribution of Various Countries in North America, $Million, 2019 and 2030
Figure 13.6: U.S. SERD Therapeutics Market, $Million, 2019-2030
Figure 13.7: Canada SERD Therapeutics Market, $Million, 2019-2030
Figure 13.8: Europe SERD Therapeutics Market, $Million, 2019-2030
Figure 13.9: Europe: Market Dynamics
Figure 13.10: Revenue Contribution of Various Countries in Europe, $Million, 2019 and 2030
Figure 13.11: U.K. SERD Therapeutics Market, $Million, 2019-2030
Figure 13.12: Germany SERD Therapeutics Market, $Million, 2019-2030
Figure 13.13: France SERD Therapeutics Market, $Million, 2019-2030
Figure 13.14: Italy SERD Therapeutics Market, $Million, 2019-2030
Figure 13.15: Spain SERD Therapeutics Market, $Million, 2019-2030
Figure 13.16: Rest-of-Europe SERD Therapeutics Market, $Million, 2019-2030
Figure 13.17: Asia-Pacific SERD Therapeutics Market, $Million, 2019-2030
Figure 13.18: Asia-Pacific: Market Dynamics
Figure 13.19: Revenue Contributions of Various Countries in Asia-Pacific, $Million, 2019 and 2030
Figure 13.20: China SERD Therapeutics Market, $Million, 2019-2030
Figure 13.21: Japan SERD Therapeutics Market, $Million, 2019-2030
Figure 13.22: Rest-of-APAC SERD Therapeutics Market, $Million, 2019-2030
Figure 13.23: RoW SERD Therapeutics market, $Million, 2019-2030
Figure 14.1: Share of Key Developments and Strategies, January 2017-December 2020
Figure 14.2: Regulatory and Legal Developments Share (by Company), January 2017 – December 2020
Figure 14.3: Synergistic Activities (by Company), January 2017 – December 2020
Figure 14.4: Funding and Business Strategy Activities (by Company), January 2017-December 2020
Figure 14.5: Market Share Analysis (by Company), 2018 and 2019
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: Amneal Pharmaceuticals Inc: Overall Financials, 2017-2019
Figure 15.3: Amneal Pharmaceuticals Inc: Sales (by Business Segment), 2017-2019
Figure 15.4: Amneal Pharmaceuticals Inc. Revenue (by Region), 2017-2019
Figure 15.5: Amneal Pharmaceuticals Inc.: R&D Expenditure, 2017-2019
Figure 15.6: Amneal Pharmaceuticals, Inc: SWOT Analysis
Figure 15.7: AstraZeneca, Plc.: Overall Financials, 2017-2019
Figure 15.8: AstraZeneca, Plc.: Sales (by Business Segment), 2017-2019
Figure 15.9: AstraZeneca, Plc.: Revenue (by Region), 2017-2019
Figure 15.10: AstraZeneca, Plc.: R&D Expenditure, 2017-2019
Figure 15.11: AstraZeneca, Plc.: SWOT Analysis
Figure 15.12: Dr. Reddy’s Laboratories: Overall Financials, 2017-2019
Figure 15.13: Dr. Reddy’s Laboratories: Sales (by Business Segment), 2017-2019
Figure 15.14: Dr. Reddy’s Laboratories: Revenue (by Region), 2017-2019
Figure 15.15: Dr. Reddy’s Laboratories: R&D Expenditure, 2017-2019
Figure 15.16: Dr. Reddy’s Laboratories: SWOT Analysis
Figure 15.17: Eli Lilly and Company: Overall Financials, 2017-2019
Figure 15.18: Eli Lilly and Company: Sales (by Business Segment), 2017-2019
Figure 15.19: Eli Lilly and Company: Revenue (by Region), 2017-2019
Figure 15.20: Eli Lilly and Company: R&D Expenditure, 2017-2019
Figure 15.21: Eli Lilly and Company: SWOT Analysis
Figure 15.22: G1 Therapeutics, Inc. Overall Financials, 2017-2019
Figure 15.23: G1 Therapeutics, Inc.: Clinical Expenses (by Product), 2017-2019
Figure 15.24: G1 Therapeutics, Inc.: R&D Expenditure, 2017-2019
Figure 15.25: G1 Therapeutics, Inc.: SWOT Analysis
Figure 15.26: Glenmark Pharmaceuticals: Overall Financials, 2017-2019
Figure 15.27: Glenmark Pharmaceuticals: Revenue (by Region), 2017-2019
Figure 15.28: Glenmark Pharmaceuticals: R&D Expenditure, 2017-2019
Figure 15.29: Glenmark Pharmaceuticals: SWOT Analysis
Figure 15.30: HBT Labs, Inc: SWOT Analysis
Figure 15.31: Hoffmann-La Roche AG: Overall Financials, 2017-2019
Figure 15.32: Hoffmann-La Roche AG: Revenue (by Business Segment), 2017-2019
Figure 15.33: Hoffmann-La Roche AG: Revenue (by Region), 2017-2019
Figure 15.34: Hoffmann-La Roche AG: R&D Expenditure, 2017-2019
Figure 15.35: Hoffmann-La Roche AG: SWOT Analysis
Figure 15.36: InventisBio: SWOT Analysis
Figure 15.37: Novartis AG: Overall Financials, 2017-2019
Figure 15.38: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 15.39: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 15.40: Novartis AG: R&D Expenditure, 2017-2019
Figure 15.41: Novartis AG: SWOT Analysis
Figure 15.42: Radius Health: Overall Financials, 2017-2019
Figure 15.43: Radius Health: Product Specific R&D Expenditure, 2017-2019
Figure 15.44: Radius Health: R&D Expenditure, 2017-2019
Figure 15.45: Radius Health: SWOT Analysis
Figure 15.46: Sanofi S.A.: Overall Financials, 2017-2019
Figure 15.47: Sanofi S.A. Net Revenue (by Business Segment), 2017-2019
Figure 15.48: Sanofi S.A.: Net Revenue (by Region), 2017-2019
Figure 15.49: Sanofi S.A.: R&D Expenditure, 2017-2019
Figure 15.50: Sanofi S.A.: SWOT Analysis
Figure 15.51: Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
Figure 15.52: Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019
Figure 15.53: Teva Pharmaceutical Industries Ltd.: Research and Development Expenditure, 2017-2019
Figure 15.54: Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 15.55: Zenopharm LLC: SWOT Analysis
Figure 15.56: Zentalis Pharmaceuticals: Overall Financials, 2017-2019
Figure 15.57: Zentalis Pharmaceuticals: Product-Specific R&D Expenditure, 2017-2019
Figure 15.58: Zentalis Pharmaceuticals: R&D Expenditure, 2017-2019
Figure 15.59: Zentalis Pharmaceuticals: SWOT Analysis
Reviews
There are no reviews yet.